Drug intelligence / Profile preview

PF-06869206

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-06869206 is an orally bioavailable, highly selective small molecule inhibitor of the renal sodium-phosphate cotransporter 2a (NaPi-IIa, encoded by the *SLC34A1* gene). Developed by Pfizer, the compound selectively blocks phosphate reabsorption in the proximal renal tubules, promoting urinary phosphate excretion (phosphaturia) and subsequently lowering circulating phosphate and parathyroid hormone (PTH) levels. It exhibits high selectivity for NaPi-IIa over other phosphate transporters such as NaPi-IIb, NaPi-IIc, PiT-1, and PiT-2. PF-06869206 has been widely utilized as a chemical tool in preclinical research to investigate phosphate homeostasis, chronic kidney disease-mineral and bone disorder (CKD-MBD), and acute kidney injury (AKI).

Other names: CPD 6FCPD6FCPD-6F

Targets

SLC34A1 (Sodium-dependent phosphate transport protein 2A)

Beyond the preview

Go deeper on PF-06869206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06869206.